NASDAQ: ONC · Life Sciences · 8 alerts · CIK 1651308
Share price
$411.29Close, Nov 16
Shares outstanding
1.48BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BeOne Medicines Ltd. filings on SEC EDGAR ↗
BeOne Medicines Principal Accounting Officer Titus B. Ball Sells $632K of Stock
Titus B. Ball, Principal Accounting Officer, sold 1,559 shares of BeOne Medicines Ltd. at $405.55 to $406.34 a share (average $405.57) in 2 transactions, worth $632K in total on Nov 6, 2026. Shares held after the trade: 0 (-100.0%).
BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $447K of Stock
Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $400.00 to $402.00 a share (average $400.82) in 2 transactions, worth $447K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).
BeOne Medicines Ltd. reported significant growth for the quarter ended September 30, 2026, with total revenues increasing to $1.89 billion from $1.41 billion in the prior year. Net income rose substantially to $384.7 million, or $3.28 per diluted ADS, driven by strong product sales and improved operating leverage despite increased R&D and SG&A spending.
BeOne Medicines reported third quarter 2026 total global revenues of $1.9 billion, a 34% increase year-over-year, driven by strong sales of its BTK inhibitor BRUKINSA. The company achieved GAAP net income of $384.7 million and raised its full-year 2026 revenue guidance to a range of $6.9 billion to $7.0 billion.
Term
3 months
“Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI.”
BeOne Medicines Insider Xiaodong Wang Sells $11.3M of Stock
Xiaodong Wang sold 31,028 shares of BeOne Medicines Ltd. at $355.56 to $366.22 a share (average $362.97) in 11 transactions, worth $11.3M in total on Oct 27, 2026. Shares held after the trade: 0 (-100.0%).
BeOne Medicines Insider Xiaodong Wang Sells $10.9M of Stock
Xiaodong Wang sold 31,027 shares of BeOne Medicines Ltd. at $349.56 to $353.24 a share (average $350.99) in 5 transactions, worth $10.9M in total on Oct 13, 2026. Shares held after the trade: 0 (-100.0%).
BeOne Medicines SVP, General Counsel Chan Henry Lee Sells $418K of Stock
Chan Henry Lee, SVP, General Counsel, sold 1,115 shares of BeOne Medicines Ltd. at $375.00 a share, worth $418K in total on Sep 30, 2026. Shares held after the trade: 0 (-100.0%).
BeOne Medicines Insider Xiaodong Wang Sells $11.3M of Stock
Xiaodong Wang sold 31,028 shares of BeOne Medicines Ltd. at $356.97 to $367.23 a share (average $364.79) in 10 transactions, worth $11.3M in total on Sep 28, 2026. Shares held after the trade: 738 (-95.2%).